Home / Biosimilars / General / Innovation over imitation: New FOBs technologies, players

Innovation over imitation: New FOBs technologies, players Posted 03/02/2010

In an article by Xencor President and CEO Bassil Dahiyat, published in Pharmaceutical Executive on 4 November 2009, tables are presented on new technologies for creating ‘biobetter’ follow-on biologics (FOBs) and potential ‘Big Pharma’ players in FOBs.

New technologies to create the next generation of biologicals: the ‘biobetters’

Technology

Advantages

Antibody and protein engineering, e.g., antibody Fc engineering

- Improved potency

- Superior half-life and dosing

- New IP exclusivity period

Cell line technologies

- Improved safety

- Scalability

- Increased productivity

Manufacturing technologies

- Enhanced stability and delivery

- Improved formulation

Potential pharmaceutical players in FOBs

Company

Biologicals capabilities

Amgen

- Established biologicals manufacturer

- Track record of launching next-generation
products, e.g. Aranesp

AstraZeneca

- Medimmune facility acquisition; biologicals

expertise

Biogen Idec

- Established biologicals manufacturer

Boehringer Ingelheim

- Kemwell facility collaboration

- Strategic alliance with Laureate Pharma

- Partnership with Inno Biologics

Daiichi-Sankyo

- Ranbaxy asset acquisition

- License agreement with Crucell and DSM

Biologics

Eli Lilly

- ImClone asset acquisition

Merck

- GlycoFi technology

- Insmed facility acquisition

- BioVentures Unit, plan to launch 6 FOBs 2012-

2017

Boehringer Ingelheim

- Kemwell facility collaboration

- Strategic alliance with Laureate Pharma

- Partnership with Inno Biologics

Novartis

- Sandoz generics division

- Dedicated biologicals unit

Pfizer

- Aurobindo collaboration: generics expertise

- Pharmacia/Chesterfield facility acquisition

- PowderMed and Rinat Neurosciences

acquisitions

(see also, Innovation over imitation - How to deliver FOBs on the bottom line, Innovation over imitation: Charting the FOBs landscape, Innovation over imitation: Tools to compete and win with ‘biobetter’ FOBs, Innovation over imitation: High-cost biosimilar FOB development, slow uptake and Innovation over imitation: ‘Biobetter’ follow-on biologics)

Reference:

Bassil Dahiyat. Innovation Over Imitation. Pharmaceutical Executive. 2009 November 4.

Source: Pharmaceutical Executive

Comments (0)